No Data
No Data
Beijing Sl Pharmaceutical: Beijing SL Pharmaceutical Co., Ltd. announces its performance forecast for the first half of 2024.
Beijing SL Pharmaceutical (002038.SZ) issued a profit warning, expecting a net income of 28 million yuan to 42 million yuan in the first half of the year, a decrease of 86.76% to 91.17%.
Beijing SL Pharmaceutical (002038.SZ) released its performance forecast for the first half of 2024, expecting a net income of 28 million yuan to 42 million yuan attributable to shareholders of the listed company, a year-on-year decrease of 86.76% to 91.17%. During the reporting period, the net income attributable to shareholders of the listed company decreased significantly compared with the same period of the previous year, mainly due to the fair value change of trading financial assets and available-for-sale financial assets in non-recurring gains and losses during this reporting period. The fair value change gains and losses for January-June 2023 were 0.108 billion yuan, and for January-June 2024
Beijing SL Pharmaceutical (002038.SZ) has obtained the registration certificate for pharmaceutical of ammonium sulfate glucosamine capsule.
Beijing SL Pharmaceutical (002038.SZ) announced that it has recently received the Drug Registration Certificate for aminoacridine sulfate capsules (trade name: Jining) issued and approved by the National Medical Products Administration (NMPA). Aminoacridine is a naturally occurring monosaccharide in human physiological state and is an essential substance for the synthesis of proteoglycans in human joint cartilage matrix. It can stimulate chondrocytes to produce polysaccharides with normal polymeric structure, improve the repair ability of chondrocytes, inhibit enzymes that damage cartilage (such as collagenases and phospholipase A2), and prevent damage to cells from excessive.
Beijing SL Pharmaceutical (002038.SZ) has obtained the registration certificate for Yipaisitapian pharmaceutical.
On June 28th, Gelunhui reported that Beijing SL Pharmaceutical (002038.SZ) announced that it has received the Drug Registration Certificate for Ipsitan Tablets (trade name: Yidian) (50mg) issued by the National Medical Products Administration. The company submitted a listing application to the National Medical Products Review Center on February 9th, 2023 and was accepted. Ipsitan tablets are mainly used for the treatment of diabetic neuropathy. Ipsitan is a reversible non-competitive inhibitor of aldose reductase, which selectively inhibits aldose reductase and improves the peripheral neuropathy complications of diabetes by inhibiting neural intracellular myo-inositol accumulation.
Beijing SL Pharmaceutical (002038.SZ): Annual equity distribution in 2023, 10 dividends of 1.5 yuan, with a record date on July 3.
Beijing SL Pharmaceutical (002038.SZ) announced on June 27 that the company's annual equity distribution plan for 2023 is to distribute RMB 1.5 in cash (including tax) for every 10 shares to all shareholders based on the total existing share capital of the company minus 0 repurchased shares, totaling 1,027,350,000 shares. The registration day for this equity distribution is July 3, 2024, and the ex-rights and ex-dividend day is July 4, 2024.
Director Liang Shujie of Beijing SL Pharmaceutical (002038.SZ) plans to reduce her shareholding by no more than 500,200 shares.
Beijing SL Pharmaceutical (002038.SZ) announced that director and board secretary Liang Shujie plans to resign in July 2024.
No Data